Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on May 4, 2023. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

ENDOTOXIN, STERILITY AND GENERAL SAFETY TESTING SERVICES

Awarded
NOI-NIAID-23-2170180Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

Contract Value

$21,190

NAICS

541380 - Testing Laboratories and Services

Place of Performance

Bethesda, MD, 20814, USA

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded
Posted

Presolicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA

Full Description

Show more
This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Bioreliance, Rockville, MD 20850 Requirements list: 1) LAL Test for Endotoxin (Quantitative, Kinetic, Chromogenic, Assay) 2) General Safety Test, 21 CFR 610.11 GMP 3) Isolator Sterility Testing Using a Direct Inoculation Method (Up to 250 mL TA or 40 vials) 4) Rabbit Pyrogen Test GMP Sole Source Justification: BioReliance is located in Rockville, MD. BioReliance uses standard protocols that are established with the FDA and require no additional explanation to the FDA. The specific tests in this request are Endotoxin (LAL Test for Endotoxin, Quantitative, Kinetic, Chromogenic, Assay), sterility (Isolator Sterility Testing Using a Direct Inoculation Method), general safety (General Safety Test, 21 CFR 610.11 GMP), and pyrogenicity (Rabbit Pyrogen Test GMP). These tests are required for clinical trial approval from the Food and Drug Administration (FDA). The requested tests are for evaluation and characterization of the vaccine product before use in humans; specifically, endotoxin, sterility, and general safety testing of the finished vaccine product; and endotoxin and sterility testing on the intermediate production step. The testing must be done on fresh sample, never being frozen. These tests will show the LMIV and the FDA if the product is safe for use in NIAID's clinical trials. Bioreliance is the approved vendor to perform the testing and provide the test results required by the FDA. These services are needed for quality control testing of the Pfs230D1-CRM197 Drug Product as part of initial characterization studies and in support of investigational new drug (IND) applications to the FDA. Bioreliance is the approved vendor to perform the testing, and provide the quarterly test results required by the FDA for this project. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-23-2170180 to Diana Rohlman at contact@example.gov by 4:00 pm eastern standard time, May 11, 2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 811210
New
Federal
1-Year OEM Service Contract - (2) Revvity Celigo S Imaging Instruments (VRC)
Solicitation # NOI-NIAID-27-2279300
The National Institutes of Health NIAID intends to award a firm-fixed price sole source contract to Revvity Health Sciences, Inc. for a one-year maintenance and service agreement for two Revvity Celigo S imaging instruments. The period of performance is scheduled from November 15, 2026, through November 14, 2027. This procurement is categorized under NAICS code 811210 for electronic and precision equipment repair and maintenance. The government is utilizing statutory authority 41 U.S.C. 3304(a)(1) and FAR 6.302.1(b)(1)(i), asserting that Revvity Health Sciences is the only responsible source capable of satisfying the requirement due to their proprietary access to diagnostic tools, service documentation, and genuine replacement parts. The scope of work includes priority response for unlimited repair travel, labor, and parts, as well as remote support and minor hardware and software updates to ensure the instruments meet manufacturer specifications. While the government intends to negotiate directly with the OEM, interested qualified sources were invited to submit capability statements by November 4, 2026, to the contracting officer, Linda Smith, and acquisition specialist, Jessica Emerson. The final award is expected to be issued within five days of the notice closing.
Electronic and Precision Equipment Repair and Maintenance

POSTED

4 days ago

DEADLINE

in 6 days
View Details
NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

in about 1 month
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS